Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- English Abstract1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Rev Rhum Mal Osteoartic1
Search Results
Sort by
- ArticlePeyron JG.Rev Rhum Mal Osteoartic. 1977 Feb;44(2):135-9.In lathyrism, the toxic agent directly blocks the development of the transverse links in the collagen fibre, while in bovine dermatosparaxis there is a deficiency of procollagen peptidase. Of the many clinical forms of the Ehlers-Danlos syndrome, some are due to a deficiency of lysine oxidase, others to deficiency of lysine hydroxylase and still others to procollagen peptidase deficiency. The essential deficiency in Marfan's disease is still unknown, but that in homocystinuria causes blocking of the groups necessary to form the transverse links. In osteogenesis imperfecta, which is probably a heterogeneous group, there is deficient consolidation of the collagen fibrils, the cause of which is still unknown. One possibility is a quantitative imbalance between chains of different types. In scleroderma there is excessive synthesis of an apparently normal connective tissue; the cause of this is also still unknown.
- BookMitchell L. Shiffman, editor.Contents:
Part I. Natural history of chronic HCV
1. Epidemiology of chronic HCV / Gary L. Davis
2. Acute HCV / Katja Deterding, Heiner Wedemeyer, and Michael P. Manns
3. Assessing the progression of chronic HCV to cirrhosis / Gonzolo Crespo, Stella M. Martinez, and Xavier Forns
4. Chronic HCV and steatosis / Dawn McDowell Torres and Stephen A. Harrison
5. Chronic HCV and hepatocellular carcinoma / Morris Sherman
6. Extrahepatic manifestations of chronic HCV / Vincenza Calvaruso and Antonio Craxì
7. Chronic HCV and HIV coinfection / Patrick Ingiliz, Maud Lemoine, and Yves Benhamou
8. Chronic HCV in patients with renal disease / Paul Martin and Fabrizio Fabrizi
9. Does treatment alter the natural history of chronic HCV? / Fasiha Kanwal and Bruce R. Bacon
Part II. Treatment of chronic HCV with interferon-based therapy
10. Treatment with interferon and ribavirin / William Kemp and Stuart K. Roberts
11. Immune modulators and other agents / Edgar D. Charles and Ira M. Jacobson
12. Measuring HCV RNA and assessing virologic response / Jean-Michel Pawlotsky
13. Response-guided therapy / Mitchell L. Shiffman
14. Managing the side effects of therapy / Curtis Cooper
15. Genetics of virologic response / Alison B. Jazwinski and Andrew J. Muir
16. Maintenance therapy with peginterferon / Raza Malik and Nezam H. Afdhal
Part III. Anti-viral therapy for chronic HCV
17. Antiviral targets in HCV / B. Kronenberger and S. Zeuzem
18. Mutations and the development of anti-viral resistance / Anna Maria Geretti and Geoff Dusheiko
19. Peginterferon, ribavirin and anti-viral triple therapy / Patrick Marcellin, Nathalie Boyer, and Tarik Asselah
20. Treating chronic HCV without interferon and/or ribavirin / Edward J. Gane
21. Maintenance therapy with oral antiviral agents / Andrew Aronsohn and Donald Jensen
Part IV. Liver transplantation for chronic HCV
22. Natural history of chronic HCV after liver transplantation / Bart J. Veldt and Michael R. Charlton
23. Use of HCV-positive organs in patients with and without chronic HCV / Elizabeth C. Verna and Robert S. Brown Jr.
24. Treating HCV prior to liver transplantation / Alvaro Martinez-Camacho, Brett E. Fortune, and Gregory T. Everson
25. Treating HCV after liver transplantation / Michael Chang, Hubert Sung, and Sammy Saab.Digital Access Springer 2012